Citius Oncology (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR), has entered into a distribution services agreement with Cardinal Health (NYSE:CAH). This ...

Cardinal Health's growth faces challenges from tariff risks, regulatory uncertainties, and competitive pressures. Learn more ...

Cardinal Health’s (CAH) robust growth in pharmaceutical distribution and oncology drugs positions it to capitalize on ...

Cardinal Health (NYSE: CAH) announced today the U.S. launch of its multi-parameter, single-patient use monitoring cable and ...

Cardinal Health Inc. (NYSE:CAH) announced the US launch of its new Kendall DL Multi System. This multi-parameter, ...

Fintel reports that on June 3, 2025, Wells Fargo upgraded their outlook for Cardinal Health (NYSE:CAH) from Equal-Weight to ...

Analysts are intrested in these 5 stocks: ( ($CAH) ), ( ($DG) ), ( ($SNOW) ), ( ($CEG) ) and ( ($CRWD) ). Here is a breakdown of their recent ...

Wells Fargo on Tuesday upgraded medical distributors Cardinal Health (NYSE:CAH) and Cencora (NYSE:COR) to Overweight from Equal Weight, citing a strong industry backdrop as a major reason for both ...

Key Insights Institutions' substantial holdings in Cardinal Health implies that they have significant influence ...

This was the stock's second consecutive day of gains.

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.

Wells Fargo analysts upgraded Cardinal Health, Inc. (NYSE:CAH)’s stock to “Overweight” from “Equal Weight,” lifting the price ...